+

WO2012006368A3 - Compositions et méthodes pour traiter la grippe - Google Patents

Compositions et méthodes pour traiter la grippe Download PDF

Info

Publication number
WO2012006368A3
WO2012006368A3 PCT/US2011/043095 US2011043095W WO2012006368A3 WO 2012006368 A3 WO2012006368 A3 WO 2012006368A3 US 2011043095 W US2011043095 W US 2011043095W WO 2012006368 A3 WO2012006368 A3 WO 2012006368A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating influenza
combination
influenza
Prior art date
Application number
PCT/US2011/043095
Other languages
English (en)
Other versions
WO2012006368A2 (fr
Inventor
David E. Anderson
Andrei Ogrel
Ronald Erwin Boch
Jeff Baxter
Original Assignee
Variation Biotechnologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies, Inc. filed Critical Variation Biotechnologies, Inc.
Publication of WO2012006368A2 publication Critical patent/WO2012006368A2/fr
Publication of WO2012006368A3 publication Critical patent/WO2012006368A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions et des méthodes pouvant servir à traiter la grippe. Lesdites compositions et méthodes sont fondées sur le développement de certaines compositions qui renferment un antigène hémagglutinine du virus de la grippe en association avec des vésicules lipidiques qui comportent un tensioactif non ionique (NISV) et/ou en association avec un adjuvant de type agoniste du TLR-3. Dans certains modes de réalisation, les compositions restent actives même si elles ne sont pas conservées dans un système de chaîne du froid normalisé (à savoir, elles sont thermostables).
PCT/US2011/043095 2010-07-06 2011-07-06 Compositions et méthodes pour traiter la grippe WO2012006368A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36189910P 2010-07-06 2010-07-06
US61/361,899 2010-07-06
US201161431278P 2011-01-10 2011-01-10
US61/431,278 2011-01-10

Publications (2)

Publication Number Publication Date
WO2012006368A2 WO2012006368A2 (fr) 2012-01-12
WO2012006368A3 true WO2012006368A3 (fr) 2012-03-15

Family

ID=45441782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/043095 WO2012006368A2 (fr) 2010-07-06 2011-07-06 Compositions et méthodes pour traiter la grippe

Country Status (1)

Country Link
WO (1) WO2012006368A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005772A1 (fr) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Procédés pour préparer des vésicules et formulations produites à partir de ces procédés
CA2767392C (fr) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Procedes de preparation de vesicules et formulations obtenues a partir de celles-ci
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) * 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264273A1 (en) * 2003-06-18 2007-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingoid polyalklamine conjugates, isomers and uses thereof
US20100080844A1 (en) * 2002-07-05 2010-04-01 Andrew David Bacon Method to enhance an immune response of nucleic acid vaccination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100080844A1 (en) * 2002-07-05 2010-04-01 Andrew David Bacon Method to enhance an immune response of nucleic acid vaccination
US20070264273A1 (en) * 2003-06-18 2007-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingoid polyalklamine conjugates, isomers and uses thereof

Also Published As

Publication number Publication date
WO2012006368A2 (fr) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2012006367A3 (fr) Compositions et méthodes pour traiter la grippe
WO2012006368A3 (fr) Compositions et méthodes pour traiter la grippe
WO2009001217A3 (fr) Vaccins antigrippaux à faible teneur en additifs
WO2007098186A3 (fr) Compositions d'adjuvant et de vaccin
CL2014002509A1 (es) Una composicion que comprende por lo menos una fuente de boro y por lo menos una fuente de silicio; producto que comprende sustrato y la composicion; un metodo para proporcionar un producto recubierto; uso de la composicion.
MX2014008008A (es) Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.
WO2013054199A3 (fr) Antigènes de cmv et leurs utilisations
WO2009114207A3 (fr) Vaccins de flavivirus défaillant sur le plan de la réplication et vecteurs de vaccin
WO2010119343A8 (fr) Compositions pour l'immunisation contre staphylococcus aureus
MX2010008799A (es) Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
WO2012100224A3 (fr) Préparation de réseaux métal- triazolate
WO2012177924A3 (fr) Mutants du virus de la grippe et utilisations
WO2011142858A3 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
WO2009085025A3 (fr) Vaccin
WO2012121547A3 (fr) Composition adhésive pour un film de traitement de tranche
EP2537822A3 (fr) Article composite incluant une couche d'oxycarbure de silicium
WO2008054481A3 (fr) Meilleures compositions de virus influenza inactivé
WO2012080833A3 (fr) Formes pharmaceutiques permettant une libération contrôlée
CL2013001737A1 (es) Composicion para limpieza que comprende un tensioactivo no ionico, nanoparticulas de base inorganica y un tensioactivo secundario; formulacion de limpieza lista para usarse que comprende a dicha composicion; y composicion para la limpieza de superficies duras.
WO2013055877A3 (fr) Ensemble serrure à barillet à éléments non rotatifs
WO2009120380A3 (fr) Vecteurs de rhinovirus recombinants
ECSP13013094A (es) Composiciones de limpieza de sal colina
MX2015013832A (es) Composicion de vacuna y metodo de uso.
NZ606087A (en) Influenza vaccine
WO2013111012A3 (fr) Procédés et compositions pour agents thérapeutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804306

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载